Εκπαιδευτικά προγράμματα
Λίστα αντικειμένων
Results of the Prospective Randomized HOVON-96 Trial in
Recipients of
Matched Related and Unrelated Donors were presented in ASH
2019, plenary
session
PTCY is better than CSI standrd treatment
https://ashpublications.org/blood/article-abstract/134/Supplement_1/1/427807/Post-Transplantation-Cyclophosphamide-after?redirectedFrom=fulltext
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Verigou
General principles
- We use the lowest effective dose of prednisone or
methylprednisolone.
- We use topical therapy to supplement systemic treatment. (eg
oral budesonide together with beclomethasone)
-We use follow-up endoscopy to evaluate the response to
treatment in patients with persistent
diarrhea. Absence of clinical or...
NPM1_Spyridonidis_EAE_2019
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Verigou
A paper illustrating the hardle in making decisions in
BMT.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Verigou
Presenter: Dr Liga
Participants: Prof.Spyridonidis, Dr Spyridis, Dr Verigou
A retrospective matched paired analysis of EBMT
shows the superiority in
regards to GFRS of PTCY vs ATG in MMUD transplantation.
Prospective
randomized should confirm these reults.
Presenter: Prof.A Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Verigou
In cases of relapse after allo-HCT, up to 50% of patients
have
cytogenetic or molecular evolution of their disease
[15].A
recent analysis in patients with MDS suggested that
relapse
after allo-HCT is driven by subclones evolving from
founding
clones existing before allo-HCT but harboring new
aberrations
[11], arguing for clonal...
Νεότερα δεδομένα στη θεραπευτική αντιμετώπιση της
Οξείας Λεμφοβλαστικής Λευχαιμίας με τη σύγχρονη ανοσοθεραπεία.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Verigou
Long term results of the phase III study were published.
They confirm
our practice in our Tx center
Presenter: Prof. Spyridondis
Particpants: Dr Liga, Dr Spyridis, Dr Verigou
Acute GVHD prophylaxis plus ATLG after myeloablative
allogeneic
haemopoietic peripheral blood stem-cell transplantation
from
HLA-identical siblings in patients with acute myeloid
leukaemia...
Optimal conditioning for ALL. Does it
exist?
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Verigou
Is an HLA-DRB1*1454/HLA-DRB1*1401 mismatchan acceptable
mismatch in
hematopoietic stemcell transplantation?
We discussed the role of such potential mismatches. We
discussed the
G-coding and the imporance of typoing at exon 2 and
3
An abstract was presented
Oudshoorn, Machteld & Lie, John & Roelen, Dave &
Verduijn, Willem &
Claas, Frans....
We discussed a phase II study on LEN/AZa or treatment
relapse after
transplantation.
Presenter:Prof Spyridonidis
Participants:Dr Liga,Dr Spyridis, Dr Fragopanagou, Dr
Verigou
We discussed a case of a
young AML patient with PTPN11 mutated (Glu76Lys, missense,
NPM1 neg/ flt3 ITD neg)
In a study (Hou et al, Leukemia volume 22, pages 1075–1078
(2008) (https://doi.org/10.1182/blood-2018-99-110319)
PTPN11 mutations were found in 5.1% adult AML patients and they
were exclusively missense...
According to bibliography, G-CSF administration on day -1, 8 or
during febrile neutropenia is not relevant with the progression of
the disease. In contrast, G-CSF administration reduces TRM and
can accelerate ANC recovery.
As a result, we decided to administer G-CSF from day 15 (from
the...
We presented a retospective analysis of BEAM vs BuCYVP16
in HL.
BEAM conditioning before AHSCT resulted in a statistically
significant
improved PFS and OS and lower relapse when compared with
BUCYVP16.
Patients with shorter remission time from diagnosis and in
non-CR at
time of AHSCT benefited most from...
When, Where, and How to use FLT3 inhibitors?
What is their value? What are the open questions.
Presenter:Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr
Katsaouni
We discussed an excellent review on mechanisms of relapse
and its
treatment.
- Major mechanisms of relapse include HLA loss, HLA
down-regulation, and expression of
coinhibitory ligands.
- Combination of donor lymphocyte infusion with
immunomodulating agents and tyrosine kinase
inhibitors may enhance the
graft-versus-leukemia (GVL) effect.
- Immune checkpoint inhibitors can induce a...
Στα πλαίσια ενημέρωσης, την Τρίτη 9/4/2019
πραγματοποιήθηκε, στην αίθουσα σεμιναρίων της Παθολογικής κλινικής,
παρουσίαση του φαρμακου Cresemba από εκπροσώπους της εταιρείας
Pfizer.
We discussed current concepts and treatment of HCV.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni
We discussed a case for BL/BLL which was referred for
HSCT. We reviewed the literature regarding BL/ BLL/
DLBCL.
In the 2008 revisions to the WHO classification, atypical
BL/BLL is no longer formally recognized; many of these cases
are
now classified as BL, whereas others are...